OSI Pharmaceuticals to Announce First Quarter 2009 Financial Results on April 29, 2009
April 16 2009 - 9:00AM
Business Wire
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that
its first quarter 2009 financial results will be released on April
29, 2009, after the markets close. Following the announcement,
OSI�s management will host a live conference call and webcast at
5:00 p.m. Eastern Time to review the Company�s financial results,
product portfolio and business developments.
To access the live webcast or the archive via the Internet, log
on to www.osip.com. Please connect to the Company's website at
least 15 minutes prior to the conference call to ensure adequate
time for any software download that may be needed to access the
webcast. Alternatively, please call 1-877-719-9791 (U.S.) or
1-719-325-4824 (international) to listen to the call. The
conference ID number for the live call is 5668462. Telephone replay
is available approximately two hours after the call. To access the
replay, please call 1-888-203-1112 (U.S.) or 1-719-457-0820
(international). The conference ID number is 5668462.
About OSI
Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and
changing lives" by discovering, developing and commercializing
high-quality, novel and differentiated personalized medicines
designed to extend life and improve the quality of life for
patients with cancer and diabetes/obesity. For additional
information about OSI, please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. Factors that might cause such
a difference include, among others, OSI's and its collaborators'
abilities to effectively market and sell Tarceva and to expand the
approved indications for Tarceva, OSI�s ability to protect its
intellectual property rights, safety concerns regarding Tarceva,
competition to Tarceva and OSI�s drug candidates from other
biotechnology and pharmaceutical companies, the completion of
clinical trials, the effects of FDA and other governmental
regulation, including pricing controls, OSI's ability to
successfully develop and commercialize drug candidates, and other
factors described in OSI Pharmaceuticals' filings with the
Securities and Exchange Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More OSI Pharmaceuticals, Inc. News Articles